Aptevo Therapeutics
APVO
0 hedge funds and large institutions have $5.99M invested in Aptevo Therapeutics in 2021 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
86% less capital invested
Capital invested by funds: $42.1M → $5.99M (-$36.1M)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$27.2M |
| 2 |
RI
RTW Investments
New York
|
-$4.34M |
| 3 |
TCM
Towercrest Capital Management
Newtown,
Pennsylvania
|
-$3.26M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$237K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$211K |
APVO Hedge Fund Activity: Q4 2021 in Review
0 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2021, worth a combined $5.99M — down 86% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of APVO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Tang Capital Management, exiting entirely with an estimated $27.2M sold.
- 0 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2021, down from 1 in Q3 2021.
- Funds reported $5.99M of Aptevo Therapeutics stock for Q4 2021, down 86% quarter-over-quarter.
- 0 funds opened new Aptevo Therapeutics positions in Q4 2021 and 1 closed out, a net change of -1 holder.
- The largest Aptevo Therapeutics seller in Q4 2021 was Tang Capital Management, an estimated $27.2M sold.
Based on aggregated 13F filings for Q4 2021.